Using Biomarker Testing to Personalize Metastatic Triple-Negative Breast Cancer Care

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman discuss the essential role of comprehensive biomarker testing in guiding individualized treatment decisions for patients with metastatic triple-negative breast cancer (mTNBC). NP Zafman explains how assessment of biomarkers, including PD-L1 expression, germline BRCA status, and HER2-low expression, helps identify appropriate treatment options and supports a more personalized approach to care. The faculty emphasize that mTNBC is a biologically heterogeneous disease and that treatment decisions should be tailored to each patient's tumor characteristics rather than relying on a one-size-fits-all strategy. They also highlight how advances in molecular profiling have expanded therapeutic options and improved the ability to sequence treatments based on individual patient and disease factors. Throughout the discussion, the speakers reinforce the importance of integrating biomarker testing into routine clinical practice to support evidence-based treatment planning and optimize outcomes for patients with metastatic triple-negative breast cancer.